Source: BioPharma-Reporter

ADVANZ PHARMA: EMA accepts Alvotech and Advanz Pharma's Marketing Authorization Application for biosimilar of J&J's Simponi

The Simponi biosimilar, AVT05, has shown positive top-line results in patients with moderate to severe rheumatoid arthritis.

Read full article »
Est. Annual Revenue
$100-500M
Est. Employees
500-1.0K
Steffen Wagner's photo - CEO of ADVANZ PHARMA

CEO

Steffen Wagner

CEO Approval Rating

82/100

Read more